A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages 615-628

  Modlin, Irvin M ^a   Drozdov, Ignat ^a   Alaimo, Daniele ^a   Callahan, Stephen ^a   Teixiera, Nancy ^a   Bodei, Lisa ^a   Kidd, Mark ^a  

^a Wren Laboratories   (United States)

Author keywords

Biomarker; Carcinoid; Chromogranin A; Gastroenteropancreatic; Monoanalyte; Multianalyte; Multigene transcript; NET; Neuroendocrine; Neurokinin A; Pancreastatin; PCR; Proton pump inhibitor; PYY

Indexed keywords

BIOLOGICAL MARKER; CHROMOGRANIN A; EVEROLIMUS; NEUROKININ A; OCTREOTIDE; PANCREASTATIN; PANCREAS HORMONE; PANCREASTATIN-52; TUMOR MARKER;

ADULT; AGED; ARTICLE; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DUODENUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER METASTASIS; MALE; MEASUREMENT; MIDDLE AGED; NEUROENDOCRINE TUMOR; PANCREAS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; BLOOD; BLOOD EXAMINATION; COMPARATIVE STUDY; NEUROENDOCRINE TUMORS; REPRODUCIBILITY;

ADULT; AGED; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC TESTS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NEUROKININ A; PANCREATIC HORMONES; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905994529     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0190     Document Type: Article

References (76)

1. 2010 Biomarkers on a roll. Nature Biotechnology 28 431 (doi:10.1038/nbt0510-431)
2. Bergenfelz A, Luts L, Jensen TB & Sundler F 2000 Pancreastatin plasma levels in patients with primary hyperparathyroidism. World Journal of Surgery 24 1579-1583. (doi:10.1007/s002680010281)
3. Bergsland EK 2013 The evolving landscape of neuroendocrine tumors. Seminars in Oncology 40 4-22. (doi:10.1053/j.seminoncol.2012.11.013)
4. Calhoun K, Toth-Fejel S, Cheek J & Pommier R 2003 Serum peptide profiles in patients with carcinoid tumors. American Journal of Surgery 186 28-31. (doi:10.1016/S0002-9610(03)00115-6)
5. Castano JP, Sundin A, Maecke HR, Villabona C, Vazquez-Albertino R, Navarro E & Oberg K 2014 Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges. Cancer Metastasis Reviews 5 5.
6. Cornejo KM, Kandil D, Khan A & Cosar EF 2014 Theranostic and molecular classification of breast cancer. Archives of Pathology & Laboratory Medicine 138 44-56. (doi:10.5858/arpa.2012-0442-RA)
7. Curtis KA, Hanson DL, Kennedy MS & Owen SM 2013 Evaluation of a multiplex assay for estimation of HIV-1 incidence. PLoS ONE 8 e64201. (doi:10.1371/journal.pone.0064201)
8. Denecke T, Baur AD, Ihm C, Steffen IG, Tischer E, Arsenic R, Pascher A, Wiedenmann B & Pavel M 2013 Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors. European Journal of Radiology 82 e550-e555. (doi:10.1016/j.ejrad.2013. 06.017)
9. Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, Wong C, Chadwick C, George K, Keevil B et al. 2013 The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS ONE 8 e73679. (doi:10.1371/journal.pone.0073679)
10. Dornan WA, Vink KL, Malen P, Short K, Struthers W & Barrett C 1993 Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin g) on the expression of male rat sexual behavior. Physiology & Behavior 54 249-258. (doi:10.1016/0031- 9384(93)90107-Q)
11. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C & Hesterberg LK 2012 Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. Journal of Pharmaceutical and Biomedical Analysis 70 415-424. (doi:10.1016/j.jpba.2012.06.003)
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 45 228-247. (doi:10.1016/j.ejca.2008.10.026)
13. Engels CC, Ruberta F, de Kruijf EM, van Pelt GW, Smit VT, Liefers GJ, Matsushima T, Shibayama M, Ishihara H, van de Velde CJ et al. 2013 The prognostic value of apoptotic and proliferative markers in breast cancer. Breast Cancer Research and Treatment 142 323-339. (doi:10.1007/s10549-013-2748-y)
14. Faivre S, Ronot M, Dreyer C, Serrate C, Hentic O, Bouattour M, Bruno O, Couvelard A, Vilgrain V & Raymond E 2012 Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Targeted Oncology 7 127-133. (doi:10.1007/s11523-012-0216-y)
15. Faltin B, Zengerle R & von Stetten F 2013 Current methods for fluorescence-based universal sequence-dependent detection of nucleic acids in homogenous assays and clinical applications. Clinical Chemistry 59 1567-1582. (doi:10.1373/clinchem.2013.205211)
16. Fleige S, Walf V, Huch S, Prgomet C, Sehm J & Pfaffl MW 2006 Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnology Letters 28 1610-1613. (doi:10.1007/s10529-006-9127-2)
17. Grimm M, Schmitt S, Teriete P, Biegner T, Stenzl A, Hennenlotter J, Muhs H-J, Munz A, Nadtotschi T, König K et al. 2013 A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 13 569. (doi:10.1186/1471-2407-13-569)
18. Guillemot J, Guerin M, Thouennon E, Montero-Hadjadje M, Leprince J, Lefebvre H, Klein M, Muresan M, Anouar Y & Yon L 2014 Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma. PLoS ONE 9 e88698. (doi:10.1371/journal.pone.0088698)
19. Hanley JA & McNeil BJ 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 29-36. (Pubitemid 12142173)
20. Hanley JA & McNeil BJ 1983 A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 839-843. (Pubitemid 13033817)
21. Hiraki S, Rinella ES, Schnabel F, Oratz R & Ostrer H 2014 Cancer risk assessment using genetic panel testing: considerations for clinical application. Journal of Genetic Counseling 7 7.
22. Hoeben BA, Starmans MH, Leijenaar RT, Dubois LJ, van der Kogel AJ, Kaanders JH, Boutros PC, Lambin P & Bussink J 2014 Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors. BMC Cancer 14 130. (doi:10.1186/1471-2407-14-130)
23. Hood L & Tian Q 2012 Systems approaches to biology and disease enable translational systems medicine. Genomics, Proteomics & Bioinformatics 10 181-185. (doi:10.1016/j.gpb.2012.08.004)
24. Hsiao RJ, Mezger MS & O'Connor DT 1990 Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney International 37 955-964. (doi:10.1038/ki.1990.71)
25. Ito T, Igarashi H & Jensen RT 2012 Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 41 505-507. (doi:10.1097/MPA.0b013e318249a92a)
26. Jensen KH, Hilsted L, Jensen C, Mynster T, Rehfeld JF & Knigge U 2013 Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scandinavian Journal of Gastroenterology 48 70-77. (doi:10.3109/00365521.2012.733953)
27. Joos GF, Vincken W, Louis R, Schelfhout VJ, Wang JH, Shaw MJ, Cioppa GD & Pauwels RA 2004 Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. European Respiratory Journal 23 76-81. (doi:10.1183/09031936.03.00101902)
28. Kanakis G & Kaltsas G 2012 Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Practice & Research. Clinical Gastroenterology 26 791-802. (doi:10.1016/j.bpg.2012.12.006)
29. Kittaneh M, Montero AJ & Gluck S 2013 Molecular profiling for breast cancer: a comprehensive review. Biomarkers in Cancer 5 61-70.
30. de Laat JM, Pieterman CR, Weijmans M, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B et al. 2013 Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. Journal of Clinical Endocrinology and Metabolism 98 4143-4151. (doi:10.1210/jc.2013-1800)
31. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B & Modlin IM 2011 The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40 111-134. (doi:10.1016/j.ecl.2010.12.001)
32. Lecci A, Capriati A, Altamura M & Maggi CA 2006 Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human. Autonomic Neuroscience 126-127 232-249. (doi:10.1016/j.autneu.2006.02. 014)
33. Lee JW & Hall M 2009 Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 877 1259-1271. (doi:10.1016/j.jchromb.2008.11.022)
34. Lewis MA & Yao JC 2013 Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Current Opinion in Endocrinology, Diabetes, and Obesity 4 4.
35. Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G et al. 2012 Limitations of chromogranin A in clinical practice. Biomarkers 17 186-191. (doi:10.3109/1354750X.2012.654511)
36. de Mestier L, Dromain C, d'Assignies G, Scoazec JY, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F et al. 2013 Evaluating neuroendocrine tumors progression and therapeutic response: state of the art. Endocrine-Related Cancer 18 18.
37. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB & Dixon JM 2009 Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. Journal of Clinical Oncology 27 1382-1387. (doi:10.1200/JCO.2008.16.8849)
38. Modlin IM, Moss SF, Chung DC, Jensen RT & Snyderwine E 2008a Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. Journal of the National Cancer Institute 100 1282-1289. (doi:10.1093/jnci/djn275)
39. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. 2008b Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 9 61-72. (doi:10.1016/S1470-2045(07) 70410-2)
40. Modlin IM, Gustafsson BI, Drozdov I, Nadler B, Pfragner R & Kidd M 2009 Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Annals of Surgical Oncology 16 487-498. (doi:10.1245/s10434-008-0251-1)
41. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV & Kidd M 2010 Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease. Annals of Surgical Oncology 17 2427-2443. (doi:10.1245/s10434- 010-1006-3)
42. Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S & Kidd M 2011 The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbeck's Archives of Surgery 27 27.
43. Modlin I, Drozdov I & Kidd M 2013a The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS ONE 8 e63364. (doi:10.1371/journal.pone.0063364)
44. Modlin I, Drozdov I & Kidd M 2013b A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress. Journal of Clinical Oncology 31 (Suppl) A4137.
45. Modlin I, Drozdov I & Kidd M 2014 Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility. Clinical Chemistry 52 419-429.
46. Neperud J, Mahvash A, Garg N, Murthy R & Szklaruk J 2013 Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy? World Journal of Radiology 5 241-247. (doi:10.4329/wjr.v5. i6.241)
47. Nicodemus KK & Malley JD 2009 Predictor correlation impacts machine learning algorithms: implications for genomic studies. Bioinformatics 25 1884-1890. (doi:10.1093/bioinformatics/btp331)
48. Oberg K, Casanovas O, Castano JP, Chung D, Delle Fave G, Denefle P, Harris P, Khan MS, Kulke MH, Scarpa A et al. 2013 Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clinical Cancer Research 19 2842-2849. (doi:10.1158/1078-0432.CCR- 12-3458)
49. O'Connor DT 1985 Plasma chromogranin A. Initial studies in human hypertension. Hypertension 7 I76-I79. (doi:10.1161/01.HYP.7.3-Pt-2.I76)
50. O'Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Gandolfi AE, Wang YZ, Boudreaux JP, Vinik AI, Go VL et al. 2010 Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas 39 611-616. (doi:10.1097/MPA. 0b013e3181c68d7a)
51. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW et al. 2008 Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS ONE 3 e2633. (doi:10.1371/journal.pone.0002633)
52. Pavel M, Kidd M & Modlin I 2013 Systemic treatment for "carcinoid": what are the options? Seminars in Oncology 40 84-99.
53. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y & Hainque B 2004 Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comparative Hepatology 3 8. (doi:10.1186/1476-5926-3-8)
54. Raines D, Chester M, Diebold AE, Mamikunian P, Anthony CT, Mamikunian G & Woltering EA 2012 A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas 41 508-511. (doi:10.1097/MPA.0b013e318243a0b6)
55. Raza A, Ali Z, Irfan J, Murtaza S & Shakeel S 2012 Analytical variables influencing the HCV RNA determination by TaqMan real-time PCR in routine clinical laboratory practice. Molecular Biology Reports 39 7421-7427. (doi:10.1007/s11033-012-1574-3)
56. Salas VM, Edwards BS & Sklar LA 2008 Advances in multiple analyte profiling. Advances in Clinical Chemistry 45 47-74.
57. Sanchez-Margalet V, Gonzalez-Yanes C, Najib S & Santos-Alvarez J 2010 Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regulatory Peptides 161 8-14. (doi:10.1016/j.regpep.2010.02.005)
58. Sawka AM, Gafni A, Thabane L & Young WF Jr 2004 The economic implications of three biochemical screening algorithms for pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 89 2859-2866. (doi:10.1210/jc.2003-031127)
59. Sciarra A, Monti S, Gentile V, Salciccia S, Gomez AM, Pannunzi LP & Di Silverio F 2005 Chromogranin A expression in familial versus sporadic prostate cancer. Urology 66 1010-1014. (doi:10.1016/j.urology.2005.05.045)
60. Siegel EG, Gallwitz B, Folsch UR & Schmidt WE 1998 Effect of human pancreastatin peptide (hP-16) on oral glucose tolerance in man. Experimental and Clinical Endocrinology & Diabetes 106 178-182. (doi:10.1055/s-0029-1211973)
61. Stridsberg M, Oberg K, Li Q, Engstrom U & Lundqvist G 1995 Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. Journal of Endocrinology 144 49-59. (doi:10.1677/joe.0.1440049)
62. Stronge RL, Turner GB, Johnston BT, McCance DR, McGinty A, Patterson CC & Ardill JE 2008 A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours. Annals of Clinical Biochemistry 45 560-566. (doi:10.1258/acb.2008.008033)
63. Syversen U, Jacobsen MB, O'Connor DT, Ronning K & Waldum HL 1994 Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropetides 26 201-206. (doi:10.1016/0143-4179(94)90131-7)
64. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA et al. 1995 Chromogranin A in human hypertension. Influence of heredity. Hypertension 26 213-220. (doi:10.1161/01.HYP.26.1.213)
65. Taupenot L, Harper KL & O'Connor DT 2003 The chromogranin- secretogranin family. New England Journal of Medicine 348 1134-1149. (doi:10.1056/NEJMra021405)
66. Tohmola N, Itkonen O, Sane T, Markkanen H, Joenvaara S, Renkonen R & Hamalainen E 2013 Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker. Clinica Chimica Acta 428C 38-43.
67. Torres-Chavolla E & Alocilja EC 2009 Aptasensors for detection of microbial and viral pathogens. Biosensors and Bioelectronics 24 3175-3182. (doi:10.1016/j.bios.2008.11.010)
68. Turner GB, Johnston BT, McCance DR, McGinty A, Watson RG, Patterson CC & Ardill JE 2006 Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 55 1586-1591. (doi:10.1136/gut.2006.092320)
69. Udupi V, Lee HM, Kurosky A & Greeley GH Jr 1999 Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatin. Regulatory Peptides 83 123-127. (doi:10.1016/S0167-0115(99)00061-0)
70. Valicherla GR, Hossain Z, Mahata SK & Gayen JR 2013 Pancreastatin is an endogenous peptide that regulates glucose homeostasis. Physiological Genomics 45 1060-1071. (doi:10.1152/physiolgenomics.00131.2013)
71. Wolin EM 2012 The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointestinal Cancer Research 5 161-168.
72. Woltering EA, Hilton RS, Zolfoghary CM, Thomson J, Zietz S, Go VL, Vinik AI, Vinik E, O'Dorisio TM & Mamikunian G 2006 Validation of serum versus plasma measurements of chromogranin A levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin A levels and symptom frequency. Pancreas 33 250-254. (doi:10.1097/01.mpa.0000235302.73615.d4)
73. Wu JT, Erickson AJ, Tsao KC, Wu TL & Sun CF 2000 Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Annals of Clinical Laboratory Science 30 175-178. (Pubitemid 30238558)
74. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. 2008 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
75. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A & Oberg KE 2011 Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology and Metabolism 96 3741-3749. (doi:10.1210/jc.2011-0666)
76. Zembutsu H, Suzuki Y, Sasaki A, Tsunoda T, Okazaki M, Yoshimoto M, Hasegawa T, Hirata K & Nakamura Y 2009 Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. International Journal of Oncology 34 361-370.